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Background: We conducted a multicentre phase II trial to investigate feasibility and antitumor activity 
of sequential FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) in patients with locally advanced 
pancreatic cancer (LAPC), (LAPC-1 trial). 
Methods: Patients with biopsy-proven LAPC treated in four hospitals in the Netherlands between Decem- 
ber 2014 and June 2017. Patients received 8 cycles of FOLFIRINOX followed by SBRT (5 fractions/8 Gy) if no 
tumour progression after the FOLFIRINOX treatment was observed. Primary outcome was 1-year overall 
survival (OS). Secondary outcomes were median OS, 1-year progression-free survival (PFS), treatment- 
related toxicity, and resection rate. The study is registered with ClinicalTrials.gov, NCT02292745, and is 
completed. 
Findings: Fifty patients were included. Nineteen (38%) patients did not receive all 8 cycles of FOLFIRINOX, 
due to toxicity ( n = 12), disease progression ( n = 6), or patients’ preference ( n = 1). Thirty-nine (78%) pa- 
tients received the SBRT treatment. The 1-year OS and PFS were 64% (95% CI: 50%-76%) and 34% (95% CI: 
22%-48%), respectively. Thirty grade 3 or 4 adverse events were observed during FOLFIRINOX. Two (5%) 
grade 3 or 4 adverse events after SBRT were observed. Two (5%) patients died due to a gastro-intestinal 
bleeding within three months after SBRT were observed. Six (12%) patients underwent a resection, all 
resulting in a complete (R0) resection. Two patients had a complete pathological response. 
Interpretation: FOLFIRINOX followed by SBRT in patients with LAPC is feasible and shows relevant antitu- 
mor activity. In 6 (12%) patients a potentially curative resection could be pursued following this combined 
treatment, with a complete histological response being observed in two patients. 
© 2019 Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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2. Introduction 
Pancreatic cancer is the fourth leading cause of cancer-related
eath with an estimated 5 year survival rate of approximately 9%
1] . At the time of diagnosis, approximately 15% of patients have
borderline) resectable disease (stage I or II), while 35% and 50% of∗ Corresponding author. 
E-mail address: c.vaneijck@erasmusmc.nl (C.H.J. van Eijck). 
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ttps://doi.org/10.1016/j.eclinm.2019.10.013 
589-5370/© 2019 Published by Elsevier Ltd. This is an open access article under the CCatients present with irresectable locally advanced pancreatic can-
er (LAPC, stage III)or metastatic disease (stage IV), respectively [2] .
APC is determined by the extent of tumour contact with the su-
erior mesenteric artery (SMA), celiac artery (CA), common hepatic
rtery (CHA), superior mesenteric vein (SMV), and portal vein (PV)
3] . The risk of a positive resection margin increases with increas-
ng tumour contact with arteries and/or veins. Several deﬁnitions
or LAPC vary in deﬁning the extent of tumour contact with the
urrounding blood vessels [4] . BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Table 1 
Dose constraints for treatment planning of SBRT. 
Organs at risk Maximum dose/fraction Total maximum dose 
Spinal Cord 5.5 Gy 27.5 Gy 
Liver < 17.5 Gy per 700 cc 
Bowel 7 Gy 35 Gy 
Kidney – ⅓ of kidneys < 15 Gray 
Stomach 7 Gy 35 Gy 
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2The American Society of Clinical Oncology recommends in-
duction chemotherapy followed by local therapies such as
(chemo)radiotherapy or local ablation in the treatment of patients
with LAPC [5] . Surgery can be considered as an option following
(chemo) radiotherapy in the absence of disease progression, if the
resection is technically feasible, with a reasonable likelihood of
reaching a radical resection [6] . 
Based upon the observed activity of FOLFIRINOX in patients
with metastatic pancreatic cancer [7] , several case series of
FOLFIRINOX in patients with LAPC have been published [8] . These
case series have shown a potential survival beneﬁt of FOLFIRINOX
treatment for patients with LAPC [9] . 
In patients with LAPC, subsequent consolidation treatment after
ﬁrst-line chemotherapy is often considered in the absence of tu-
mour progression [6] . Conventional (chemo) radiotherapy is most
frequently used [8] . However, there is a disadvantage to conven-
tional radiation due to its lack of selective tumour targeting [ 6 ,
10 ]. Stereotactic Body Radiotherapy (SBRT) could possibly improve
antitumor activity while limiting dose to surrounding organs [11] .
No prospective phase II trials investigating the role of sequential
FOLFIRINOX and SBRT in patients with LAPC have been published
to date [12] . 
We conducted a multicentre phase II trial to investigate feasibil-
ity and antitumor activity of sequential FOLFIRINOX and Stereotac-
tic Body Radiotherapy (SBRT) in patients with LAPC (LAPC-1 trial). 
2. Methods 
2.1. Study design 
Between December 2014 and June 2017 all consecutive patients
with biopsy-proven LAPC from four participating hospitals were
enrolled in this study. Ethical approval was given from all local eth-
ical committees of the participating hospitals (Erasmus University
Medical Center, Leiden University Medical Center, Maasstad Hospi-
tal, and Reinier de Graaf Group). The diagnostic work-up included
a tri-phasic CT-scan of abdomen and thorax followed by staging la-
paroscopy. LAPC was deﬁned according to the Dutch guidelines as
tumour contact with the SMA , CA , or CHA exceeding 90 ° or contact
with the SMV or PV exceeding 270 ° [13] . All patients gave writ-
ten informed consent before participating in the study (ClinicalTri-
als.gov Identiﬁer: NCT02292745). 
2.2. Patients 
The inclusion criteria were biopsy-proven LAPC, age 18–75
years, World Health Organization (WHO) performance status ≤1,
ASA classiﬁcation ≤1, no evidence of metastatic disease, largest
diameter of tumour ≤7 cm, normal renal, bone marrow, and
liver function. Exclusion criteria were prior abdominal radiother-
apy, lymph node metastasis outside the radiation ﬁeld, tumour in-
growth into stomach, other invasive malignancies diagnosed within
3-years, pregnancy or breastfeeding, serious concomitant disorders
that comprise the safety of the patient. 
2.3. Intervention 
FOLFIRINOX was started within one month after CT-scan and
staging laparoscopy in all patients. Standard FOLFIRINOX (2-h in-
travenous infusion of oxaliplatin (85 mg/m ²) followed by a 2-h in-
travenous infusion of leucovorin (400 mg/m ²) concomitantly with a
90-min intravenous infusion of irinotecan (180 mg/m ²), followed by
a bolus (400 mg/m ²) and a 46-h continuous infusion (2400 mg/m ²)
of ﬂuorouracil) was given once every two weeks for up to 8 cycles.
Dose reductions and delays were according to local practice. Inases of persisting toxicity following two dose reductions, FOLFIRI-
OX was discontinued. 
Routine CT scans were performed after 4 and 8 cycles FOLFIRI-
OX. Patients in whom no disease progression was observed af-
er the completion of FOLFIRINOX received SBRT. Before the start
f SBRT, ﬁducial markers were inserted in the tumour via endo-
copic ultrasonography guidance. Gross tumour volume (GTV) was
ontoured on a 1.25-mm thick contrast-enhanced CT scan. Clini-
al target volume (CTV) included the GTV plus geometric expan-
ion of 5 mm to include potential microscopic tumour extension.
lanning target volume (PTV) encompassed the CTV plus a 2 mm
argin. Prescription dose to the 80% isodose line of the PTV was
0 Gy in 8 Gy daily fractions. At least 95% of the prescribed dose
hould cover 95% of the PTV, though PTV was allowed to be un-
er dosage to meet the constraints of dose-limiting organs at risk
OAR). Dose constraints are summarized in table 1 . Real time tu-
our tracking was performed using the Synchrony respiratory mo-
ion tracking system with the ﬁducials. Endoscopy was performed
o implant three ﬁducials close to or within the tumour prior to
he SBRT. A CT-scan was performed 3 and 6 months after SBRT. If
he tumour was deemed resectable and no metastatic lesions were
een, an exploratory laparotomy was performed. Resectability was
eﬁned as arterial tumour contact less than 90 ° and venous tu-
our contact less than 270 °. 
.4. Outcomes 
The primary outcome of this study was the 1-year OS rate. The
econdary outcomes were 1-year progression free survival (PFS)
ate, treatment related toxicity, locoregional PFS, metastatic PFS,
nd resection rate. OS was calculated from the start of the FOLFIRI-
OX to the date of death. PFS was calculated from the start of
OLFIRINOX to the date of progression or death. Survival functions
ere estimated using the Kaplan-Meier method in SPSS (version
1). Adverse events were graded using National Cancer Institute
NCI) Common Toxicity Criteria (CTC 4.0). Radiological responses
ere assessed using RECIST 1.1 [14] . Histopathological response
as graded by the tumour regression grading of the College of
merican Pathologists. [15] 
The 1-year OS rate in a historical cohort of patients within
ur institution with LAPC treated with the combination of
racil/Tegafur plus leucovorin and celecoxib in combination with
onventional radiotherapy was 40% [16] . We hypothesized that
ith the current treatment sequence a 1-year survival rate of 60%
ould be achievable. Calculations were made with a two-sided 5%
igniﬁcance test, a power of 80%, and a 20% dropout rate. Using
ern’s design for non-randomized phase II trials, a minimum of 51
atients was needed for this study, to be able to include 42 pa-
ients for the ﬁnal analysis. [17] A log-rank test was used to com-
are survival data. 
This study is written in adherence to the CONSORT guidelines
or clinical trials, when applicable. 
.5. The role funding source 
There was no funding source for this study. 
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Fig. 1. Flowchart of the included patients. 
Table 2 
Baseline characteristics. 
Baseline characteristics N = 50 (%) or [IQR] 
Age, median 63 [53–68] 
Gender, male 25 (50) 
BMI 23.8 [21.6 – 27.6] 
Tumor origin 
Head 29 (58) 
Body 19 (38) 
Tail 2 (4) 
Pretreatment median CA 19.9 (μg/L) 171 [56–876] 
Jaundice 21 (42) 
Pretreatment median CEA (kU/L) 4.2 [3.0–10.0] 
Diabetes 12 (24) 
Abdominal pain 
Yes 39 (78) 
Missing 1 (2) 
Weight loss 
Yes 39 (78) 
Missing 6 (12) 
Maximum tumor size (mm), median 40 [12–22] 
Vascular involvement 
Venous > 270 ° 7 (14) 
Arterial > 90 ° 10 (20) 
Both 33 (66) 
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Table 3 
Grade 3 or higher adverse events for FOLFIRINOX and SBRT. 
FOLFIRINOX SBRT 
Description Grade 3 Grade 4 Grade 3 Grade 4 Grade 5 
Diarrhea 9 1 – – –
Infection 5 3 – – –
Vomiting 1 3 1 – –
Liver toxicity 2 – – – –
Neuropathy 1 – – – –
GI bleeding – 1 – 1 2 
Mucositis 1 – – – –
Fatigue – 1 – – –
Other 2 – – – –
Total 21 9 1 1 2 
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Seventy-two patients were eligible and gave informed consent.
ighteen (25%) patients were found to have metastatic disease at
taging laparoscopy, three patients had metastatic disease after
estaging imaging before treatment. 51 patients could start the as-
igned treatments. One patient withdrew consent before treatment
 Fig. 1 ). In the ﬁnal Intention to treat analysis, 50 patients (50%
ales, median age 63 years) were included. The tumour was lo-
ated in the pancreatic head in 29 (58%) patients, pancreatic body
n 19 (38%) patients, and pancreatic tail in 2 (4%) patients. Me-
ian tumour size was 40 mm [IQR 30–46]. The median pretreat-
ent serum levels of CA19-9 and CEA were 171 kU/l [IQR 56 -
76] and 4.2 ug/l [IQR 3.0 – 10.0], respectively. The median time
etween staging laparoscopy and start of treatment was 18 days
IQR 12 - 22]. All baseline characteristics are shown in table 2 . 
FOLFIRINOX was given to all 50 patients with a median of 8
ycles [IQR 4–8], with 43 (86%) patients completing 4 or moreycles. The reasons for not completing the assigned chemother-
py were toxicity ( n = 14), disease progression ( n = 6), and patient’s
reference ( n = 1). Seven (14%) patients had partial remission af-
er induction FOLFIRINOX. Dose reductions were applied in 46% of
atients. Thirty grade 3 or 4 adverse events during the FOLFIRI-
OX mainly consisted of diarrhoea ( n = 10), infection ( n = 8), vom-
ting ( n = 4), hepatic toxicity ( n = 2), neuropathy ( n = 1), gastro-
ntestinal perforation ( = 1), mucositis ( n = 1), and fatigue ( n = 1). No
eaths were attributed to FOLFIRINOX. Two patients received gem-
itabine after initial toxicity of FOLFIRINOX. Sequential to induc-
ion chemotherapy, 39 (78%) patients received SBRT. The reasons
or not starting SBRT were progression under FOLFIRINOX ( n = 6),
nd toxicity from FOLFIRINOX ( n = 5). All 39 patients received the
ssigned dose of 40 Gray. One (3%) patient had a grade 3 vomit-
ng as adverse event, one (3%) patient a grade 4 gastro-intestinal
leeding after SBRT and two (5%) patients had a grade 5 gastro-
ntestinal bleeding after SBRT. Both events were observed within
hree months after completing SBRT. In one patient a duodenal-
ancreatic ﬁstula with an aneurysm of the SMA was diagnosed,
hile the other patient refused any further diagnostics. All adverse
vents of FOLFIRINOX and SBRT are summarized in table 3 . 
After FOLFIRINOX and SBRT treatment, four (10%) patients
howed local progression, 19 (49%) distant progression, and four
10%) patients both distant and local progression. Second-line
hemotherapy for progressive disease was given in seven patients,
wo patients received FOLFIRINOX, three patients gemcitabine, and
wo patients gemcitabine with nab-paclitaxel. Seven (14%) patients
nderwent an explorative laparotomy of which six patients un-
erwent a potentially curative resection. One patient did not un-
ergo a resection due to a solitary 3 mm occult liver metastasis
ound during the operation. The patients who underwent a resec-
ion had pancreatic cancer in the head ( n = 4), and in the body
 n = 2). Histopathological examination showed a complete patho-
ogical response in two (33%) patients, moderate response in three
50%) patients, and no pathological response in one (17%) patient.
n all patients, resection margins were negative (e.g., closest mar-
in > 1 mm). Postoperative complications were seen in four pa-
ients; bile leakage ( n = 2), ischemic gastro-intestinal perforation
 = 2), bleeding ( n = 1), and delayed gastric emptying ( = 1). 
All patients had a minimum follow-up of 1 year, with a median
ollow-up of 29 months (95% CI 23–36) of patients alive at last
ollow-up. The 1-year OS rate in the intention to treat population
as 64% (95% CI 50–76). The 1-year PFS rate was 34% (95% CI 22–
8). OS and PFS rates are shown in Fig. 2 . The median OS and PFS
ere 15 (95% CI 11–18) and 9 months (95% CI: 8–10), respectively.
he 1-year OS rates for patients who had completed SBRT was 79%
95% CI 65–89), while the 1-year OS rate for patients who had also
ndergone curative resection was 83% (95% CI 44–97). The median
S for patients who had completed SBRT was 17 months (95% CI
4–21) and was 7 months (95% CI 6–8) in patients who had not
eceived SBRT ( p < 0.001). The median OS for the six patients that
4 M. Suker, J.J. Nuyttens and F.A.L.M. Eskens et al. / EClinicalMedicine 17 (2019) 10 020 0 
Fig. 2. Kaplan-Meier plot of overall survival (OS), and progression free survival 
(PFS) of all patients ( N = 50). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Kaplan-Meier of locoregional progression free survival (PFS), and metastatic 
PFS in patients after stereotactic body radiotherapy (SBRT) treatment ( N = 39). 
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sunderwent resection was 23 months (95% CI 13–34). The median
OS after starting SBRT was 10 months (95% CI 7–12). Median lo-
coregional PFS in all patients was 17 months (95% CI 11–24), 20
months (95% CI 14–28) for the SBRT group and 3 months (95% CI
2–4) for the non-SBRT group ( p < 0.001). The median distant PFS in
all patients was 11 months (95% CI 10–12), for the SBRT group 11
months (95% CI 9–13), and 3 months (95% CI 2–4) in the non SBRT
group ( p < 0.001). The locoregional and metastasis PFS are shown in
Fig. 3 . 
4. Discussion 
In this multicentre open-label phase II trial, patients with LAPC
were sequentially treated with FOLFIRINOX and SBRT consisting 5
fractions of 8 Gray. To our knowledge, this is the ﬁrst trial that has
prospectively investigated feasibility and antitumor activity of this
combined approach in patients with LAPC. The 1-year OS rate of
64% is signiﬁcantly higher than the 1-year OS rate of 40% achieved
in our own historic cohort of patients treated with Uracil/Tegafur
plus leucovorin and celecoxib in combination with conventional ra-
diotherapy. Most patients (78%) completed the assigned treatment
of FOLFIRINOX and SBRT. No deaths were attributed to the FOLFIRI-
NOX treatment, while two deaths (5%) were possibly attributable
to SBRT. The resection rate was 12%, and in all patients the resec-
tion turned out to be radical. In the last decade, FOLFIRINOX has emerged as a possible new
tandard therapy for LAPC [6] . Although no RCTs have been pub-
ished to conﬁrm this ﬁnding, many case series have demonstrated
romising survival rates of FOLFIRINOX in patients with LAPC [8] .
n this study, the progression rate after FOLFIRINOX was only 12%,
hich is very high compared to gemcitabine [10] ., which again
oints to the enhanced eﬃcacy of FOLFIRINOX compared to gemc-
tabine. Moreover, staging laparoscopy prior to systemic treatment
esults in more accurate patient selection, which could have in-
uenced the progression rate. Recent patient-level meta-analyses
f 315 patients showed even a 1-year OS rate of 80%. This some-
hat unexpected ﬁnding most likewise is the result of patient se-
ection due to the retrospective design of most of the included
tudies, as only one prospective study comprising 11 patients with
APC was included in this analysis [18] . In the patient-level meta-
nalysis about 60% of the patients received subsequent (chemo) ra-
iotherapy after FOLFIRINOX. However, in the studies that applied
T more frequently no improvement of OS was reported [8] . 
Radiotherapy can be considered as a rational local treatment
pproach in patients with LAPC in whom no metastatic disease is
een after systemic therapy [6] . Staging laparoscopy could be in-
luded in the diagnostic work-up in patients staged as LAPC on
maging, as it gives better patient selection [19] . Our study con-
rms that staging laparoscopy frequently (25% in this study) dis-
overs metastatic disease that was not seen on initial radiologic
nalyses. It is unlikely that localized treatment options alone after
ystemic therapy in patients with metastatic disease will improve
urvival. 
M. Suker, J.J. Nuyttens and F.A.L.M. Eskens et al. / EClinicalMedicine 17 (2019) 10 020 0 5 
 
c  
b  
t  
b  
t  
t  
o  
w  
p  
c  
s  
t  
i  
h  
T  
g  
S  
m  
T  
d  
r  
i  
3  
n  
a  
i  
d  
c  
3  
i  
f  
t  
p  
w  
3  
o  
l  
s  
p  
[  
O  
i  
s
 
i  
t  
p  
i  
c  
ﬁ  
e  
m  
f  
r  
s  
t  
m  
r  
s  
d  
v  
w  
a
 
w  
v  
e  
a  
m  
t
 
a  
i  
t  
1  
c  
c  
[  
s  
0
 
w  
t  
(  
u  
f  
m  
1  
I  
b  
l  
c
 
s  
c  
o  
f  
t  
s  
A  
s  
s  
m  
w  
c
 
t  
r  
(  
v  
g  
s  
i  
t  
s  
r  
o  
p
5
5
 
c  
c  
t  
l  
n  
p  
tThe ﬁrst cases of stereotactic radiotherapy for pancreatic can-
er were reported in 20 0 0 from Stanford University and showed
asic feasibility of single fraction with stereotactic radiotherapy in
he treatment of pancreatic cancer [20] . This study was followed
y an initial phase I dose escalation study with stereotactic radio-
herapy for pancreatic cancer also from Stanford University [21] . A
otal of ﬁfteen patients were enrolled and received doses of 15, 20,
r 25 Gy to the primary tumour. Five patients had acute toxicity,
hich consisted of grade 2 nausea, pain, or diarrhoea. The 6 (38%)
atients who received 25 Gy had local control of their primary pan-
reatic tumour, but all died due distant metastases. The median
urvival for the cohort was 11 months. Following this, a phase II
rial from the Stanford group aimed to integrate standard gemc-
tabine chemotherapy with stereotactic radiotherapy to address the
igh propensity of distant metastasis in pancreatic carcinoma [22] .
wo weeks or more after the stereotactic radiotherapy (25 Gy),
emcitabine was restarted and continued until disease progression.
ixteen patients were enrolled and all patients completed treat-
ent with a median survival of 11.4 months, and 1-year OS of 50%.
hirteen (81%) of 16 patients had local control, but these patients
eveloped distant progression. None of the patients had suﬃcient
esponse to undergo resection. Acute toxicity was low, but late tox-
city was severe including ﬁve grade 2 duodenal ulcers, one grade
 duodenal stenosis requiring stenting, and one grade 4 duode-
al perforation requiring surgery. Mahadevan et al. retrospectively
nalysed a planned strategy of initial chemotherapy with restag-
ng and followed by SBRT for those patients with no evidence of
istant progression [23] . Patients without metastases after two cy-
les were treated with SBRT (tolerance-based dose of 24–36 Gy in
 fractions) between the third and fourth cycle without interrupt-
ng the chemotherapy cycles. Eight (17%) of the 47 patients were
ound to have metastatic disease after two cycles of gemcitabine;
he remaining 39 patients received SBRT. The median OS for all
atients who received SBRT was 20 months. The local control rate
as 85%, while 54% of patients developed metastases. Late grade
 toxicities such as gastro-intestinal bleeding and obstruction were
bserved in three (9%) of the 39 patients. Recently, FOLFIRINOX fol-
owed by SBRT have been reported in some retrospective cohort
tudies. Mellon et al. showed a promising response rate with 21
atients receiving FOLFIRINOX followed by SBRT (5 fraction/6 Gy)
24] . Six (24%) of the 21 patients had partial response. The median
S in this study was 15 months for all patients. Our study, be-
ng the ﬁrst phase II trial that explored this combination regimen,
hows a similar antitumor activity in patients with LAPC. 
In our study 6 (12%) patients underwent resection, all resulting
n radical (R0) resections. This rate is lower than the 28% resec-
ion rate in a recent meta-analysis [25] . In our study, surgical ex-
loration after FOLFIRINOX and SBRT was only considered if imag-
ng showed “disencasement” with arterial tumour contact not ex-
eeding 90 ° and venous tumour contact not exceeding 270 °, as de-
ned by our national guidelines [13] . The decision to perform the
xploration was made during our multidisciplinary tumour board
eetings, where the surgeon makes the ﬁnal call on the technical
easibility of the surgery. Imaging after induction therapy is un-
eliable to determine local progression or response, and therefore
ome centres consider surgical exploration more liberally, provided
hat distant metastatic disease is absent [ 6 , 26 ]. However, it re-
ains uncertain whether patients will beneﬁt from surgical explo-
ation [8] . The most recent ASCO guideline suggests that patients
hould undergo a resection only after radiological response to in-
uction therapy [6] . There is a need for prospective trials to in-
estigate the role of surgical exploration and resection in patients
ith LAPC without distant disease progression after induction ther-
py. 
Grade 3 or 4 adverse event rate during FOLFIRINOX our study
as 30 events in 50 patients, which is comparable with the pre-iously reported series [25] . Four (10%) grade 3 or higher adverse
vents after SBRT were observed, with two patients suffering from
 fatal GI bleeding within 3 months after completing SBRT. These
ortality rates are comparable to reported results from the litera-
ure [27] . 
Several ablative therapies such as radiofrequency ablation (RFA)
nd irreversible electroporation (IRE) are currently being assessed
n clinical studies in patients with LAPC. [12] The median OS in pa-
ients with LAPC treated in one single centre with RFA varies from
9 to 26 months [12] . In this series no speciﬁed treatment proto-
ol was used as patients could have been treated with RFA after
hemotherapy or could have received RFA as ﬁrst-line treatment
28] . Therefore, a comparison between our study and the published
tudies on RFA is diﬃcult. Morbidity after RFA is reported between
 and 28%, while 30-day mortality ranges from 0 to 3% [28-30] . 
Several studies on IRE treatment in LAPC patients are published,
ith largest cohort that of Martin et al. consisting of 200 pa-
ients [31] . The study reports on patients receiving IRE after chemo
radiotherapy) treatment. After initial systemic treatment, patients
nderwent either IRE treatment or IRE combined with resection
or margin accentuation with a median OS of 23 months and 28
onths, respectively. Other studies reported median OS between
5 and 27 months after IRE treatment in LAPC [12] . Morbidity after
RE was reported between 10 and 57%, while mortality was found
etween 1 and 3% [12] . However, these studies are prone to se-
ection bias, because patients with rapid progression on systemic
hemotherapy were not included. 
The main limitation of the current study is that it was de-
igned as a single-arm non-randomized phase II study making any
omparison to other treatment options virtually impossible. An-
ther relevant issue is that our current deﬁnition of LAPC dif-
ers signiﬁcantly; the deﬁnition for LAPC in this trial is based on
he Dutch Pancreatic Cancer Group deﬁnition, which is more con-
ervative than the National Comprehensive Cancer Network and
HPBA/SSO/SSAT deﬁnitions for LAPC. Finally, all patients in this
tudy received FOLFIRINOX according to the schedule that was de-
cribed in the PRODIGE 4 trial [18] . However, several studies have
eanwhile reported on a so-called modiﬁed FOLFIRINOX schedule
hich uses a 25% reduction of 5-FU gives comparable survival out-
omes, but with a decreased toxicity proﬁle [32] . 
In conclusion, FOLFIRINOX followed by SBRT existing of 5 frac-
ions of 8 Gray was safe and feasible. This resulted in a 1-year OS
ate of 64%, and a 1-year PFS rate of 34%. Furthermore, ultimately 6
12%) patients underwent potentially curative R0 resection. In our
iew, this warrants further investigation of a more aggressive sur-
ical approach in randomized trials. Nonetheless, distant progres-
ion remains the biggest concern in LAPC patients. Therefore, stud-
es are needed to further explore the potential role of this pro-
ocolled regimen combined with other systemic therapies. For in-
tance, immunotherapy is emerging as a synergetic treatment to
adiotherapy with promising results [ 33 , 34 ]. Sequential treatment
f chemotherapy and SBRT combined with immunotherapy, could
otentially improve outcomes in this group of patients. 
. Research in context 
.1. Evidence before this study 
Pancreatic cancer is projected to be the second most common
ancer related cause of death by 2030. One-third of all pancreatic
ancer patients have locally advanced pancreatic cancer at presen-
ation. FOLFIRINOX has been the ﬁrst-choice systemic therapy for
ocally advanced pancreatic cancer, although level I evidence is still
eeded to conﬁrm superiority of FOLFIRINOX. Local ablative thera-
ies in the locally advanced setting could be considered in addition
o systemic therapy, however, prospective clinical trials are scarce. 
6 M. Suker, J.J. Nuyttens and F.A.L.M. Eskens et al. / EClinicalMedicine 17 (2019) 10 020 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[  
 
 
 
 
 
[  
 
[  
 
 
 
 
[  
 
[  
 
 
 5.2. Added value of this study 
This is the ﬁrst phase II trial that evaluated the FOLFIRINOX
followed by stereotactic body radiotherapy in patients with locally
advanced pancreatic cancer. The 1-year OS rate in the intention to
treat population was 64% (95% CI 50–76). 
5.3. Implications of all the available evidence 
FOLFIRINOX followed by stereotactic body radiotherapy for pa-
tients with locally advanced pancreatic cancer is feasible. This pro-
tocolled regimen is promising and should be further explored in
randomized controlled trials. 
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